JP2007521835A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007521835A5 JP2007521835A5 JP2006553250A JP2006553250A JP2007521835A5 JP 2007521835 A5 JP2007521835 A5 JP 2007521835A5 JP 2006553250 A JP2006553250 A JP 2006553250A JP 2006553250 A JP2006553250 A JP 2006553250A JP 2007521835 A5 JP2007521835 A5 JP 2007521835A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- effective amount
- treating
- dietary supplement
- suspected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Claims (5)
- 有効量の請求項５に記載の組成物を含む、癌であるか癌であると疑われる患者を処置するための医薬組成物。
- 有効量の請求項１１に記載の組成物を含む、癌であるか癌であると疑われる患者を処置するための医薬組成物。
- 有効量のニコチンアミドリボシド組成物を含む、ＮＡＤ＋生合成のニコチンアミドリボシドキナーゼ経路に関連する疾患または状態を予防または処置するための栄養補助食品組成物。
- 疾患または状態が脂質障害または発作である、請求項１８に記載の栄養補助食品組成物。
- 有効量のトリプトファン、ニコチン酸またはニコチンアミドをさらに含む、請求項１８に記載の栄養補助食品組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54334704P | 2004-02-10 | 2004-02-10 | |
| PCT/US2005/004337 WO2005077091A2 (en) | 2004-02-10 | 2005-02-09 | Nicotinamide riboside kinase compositions and methods for using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007521835A JP2007521835A (ja) | 2007-08-09 |
| JP2007521835A5 true JP2007521835A5 (ja) | 2008-05-22 |
Family
ID=34860407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006553250A Pending JP2007521835A (ja) | 2004-02-10 | 2005-02-09 | ニコチンアミドリボシドキナーゼ組成物およびそれらの使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US8197807B2 (ja) |
| EP (1) | EP1723227A4 (ja) |
| JP (1) | JP2007521835A (ja) |
| AU (1) | AU2005211773B2 (ja) |
| CA (1) | CA2555675A1 (ja) |
| WO (1) | WO2005077091A2 (ja) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8114626B2 (en) * | 2004-02-10 | 2012-02-14 | Trustees Of Dartmouth College | Yeast strain and method for using the same to produce nicotinamide riboside |
| US20050227327A1 (en) * | 2004-02-10 | 2005-10-13 | Brenner Charles M | Nicotinamide riboside kinase compositions and methods for using the same |
| CA2567848A1 (en) * | 2004-06-04 | 2006-01-05 | Washington University | Methods and compositions for treating neuropathies |
| US20070014833A1 (en) * | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| WO2006105440A2 (en) * | 2005-03-30 | 2006-10-05 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
| US20060292099A1 (en) * | 2005-05-25 | 2006-12-28 | Michael Milburn | Treatment of eye disorders with sirtuin modulators |
| US20070149466A1 (en) * | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| EP2124985A4 (en) * | 2007-01-26 | 2011-06-08 | Univ Washington | METHOD AND COMPOSITIONS FOR TREATING NERVOUS ELEMENTS |
| NZ719328A (en) | 2013-10-30 | 2022-04-29 | Chromadex Inc | Nicotinamide riboside compositions for topical use in treating skin conditions |
| MX2016016071A (es) | 2014-06-06 | 2017-07-11 | Glaxosmithkline Intellectual Property (No 2) Ltd | Analogos de ribosido de nicotinamida y composiciones farmaceuticas y usos de los mismos. |
| EP3670522B1 (en) | 2014-07-24 | 2022-01-19 | W.R. Grace & CO. - CONN. | Crystalline form of nicotinamide riboside chloride |
| KR102629310B1 (ko) | 2015-03-09 | 2024-01-24 | 더블유.알. 그레이스 앤드 캄파니-콘. | 니코틴아미드 리보사이드의 결정 형태 |
| WO2016149395A1 (en) | 2015-03-16 | 2016-09-22 | ChromaDex Inc. | Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof |
| WO2016178945A1 (en) * | 2015-05-01 | 2016-11-10 | The Procter & Gamble Company | Method of improving the appearance of skin and compositions therefor using nicotinamide riboside |
| WO2017004102A1 (en) | 2015-06-29 | 2017-01-05 | The Procter & Gamble Company | Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container |
| CN108430449B (zh) | 2016-01-11 | 2023-01-24 | 宝洁公司 | 处理皮肤状况的方法以及用于其的组合物 |
| US10000520B2 (en) | 2016-03-16 | 2018-06-19 | ChromaDex Inc. | B-vitamin and amino acid conjugates ofnicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof |
| NZ747693A (en) | 2016-04-20 | 2023-07-28 | Chromadex Inc | Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors |
| EP3538099A4 (en) | 2016-11-11 | 2020-06-17 | The Queen's University of Belfast | EFFICIENT AND EVOLUTIVE SYNTHESIS OF NICOTINOYLE RIBOSIDES AND NICOTINOYLE RIBOSIDES, THEIR MODIFIED DERIVATIVES, THEIR PHOSPHORYLATED ANALOGS, THEIR CONJUGATES WITH ADENYLYLE DINUCLEOTIDE AND NEW CRISTALLY FORMULATES |
| JP7136795B2 (ja) | 2016-11-29 | 2022-09-13 | ユニバーシティー オブ アイオワ リサーチ ファウンデーション | 母体の健康および／または子の健康を向上させるためのｎａｄ前駆体の使用 |
| US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
| US10376528B2 (en) | 2017-03-10 | 2019-08-13 | Tecton Group, Llc | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor |
| EP3642214A2 (en) | 2017-06-19 | 2020-04-29 | Gangadhara Ganapati | Nicotinamide riboside derivatives and their uses |
| CN114788791A (zh) | 2017-06-23 | 2022-07-26 | 宝洁公司 | 用于改善皮肤外观的组合物和方法 |
| CA3086535A1 (en) | 2017-12-22 | 2019-06-27 | Elysium Health, Inc. | Crystalline forms of nicotinamide riboside chloride |
| CA3102288A1 (en) | 2018-07-03 | 2020-01-09 | The Procter & Gamble Company | Method of treating a skin condition |
| EP3855943A2 (en) | 2018-09-27 | 2021-08-04 | Société des Produits Nestlé S.A. | Compositions and methods using at least one glycine or derivative thereof, at least one n-acetylcysteine or derivative thereof, and at least one nicotinamide riboside or nad+ precursor |
| EP3897666A2 (en) | 2018-12-17 | 2021-10-27 | Mitopower LLC | Nicotinyl riboside compounds and their uses |
| US20220290122A1 (en) * | 2019-02-19 | 2022-09-15 | Whitehead Institute For Biomedical Research | Methods and agents for modulating mitochondrial nad levels |
| US20220125814A1 (en) * | 2019-03-21 | 2022-04-28 | Fred Hutchinson Cancer Research Center | Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor |
| EP3986420A1 (en) | 2019-06-18 | 2022-04-27 | Mitopower LLC | Nicotinyl riboside compounds and their uses |
| CN110412157A (zh) * | 2019-07-17 | 2019-11-05 | 广州金评检测研究院有限公司 | 一种烟酰胺原料中烟酸的测定方法 |
| CN114423771A (zh) | 2019-07-19 | 2022-04-29 | 生物合成股份公司 | 制备烟酰胺呋喃核糖苷盐的方法、烟酰胺呋喃核糖苷盐本身及其用途 |
| AU2021245358A1 (en) | 2020-04-01 | 2022-08-25 | Société des Produits Nestlé S.A. | Compositions and methods containing N-acetylcystein and nicotinamide riboside for prevention and treatment of neurological diseases and conditions |
| EP4157206A1 (en) | 2020-06-01 | 2023-04-05 | The Procter & Gamble Company | Method of improving penetration of a vitamin b3 compound into skin |
| US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
| EP4247187A1 (en) | 2020-11-18 | 2023-09-27 | Société des Produits Nestlé S.A. | Compositions and methods using a combination of oleuropein and nicotinamide riboside for cellular energy |
| CN112553178B (zh) * | 2020-12-25 | 2023-03-10 | 中山俊凯生物技术开发有限公司 | 热稳定性和活性增强的烟酰胺核糖激酶突变体及其编码基因和应用 |
| LT7046B (lt) | 2022-04-15 | 2024-02-12 | Vilniaus Universitetas | Hidrolazės ir jų panaudojimas |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3023787A1 (de) | 1980-06-25 | 1982-01-21 | Studiengesellschaft Kohle mbH, 4330 Mülheim | Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen |
| US4501729A (en) | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| WO1991006309A1 (en) | 1989-11-03 | 1991-05-16 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| ATE272123T1 (de) | 1993-11-09 | 2004-08-15 | Ohio Med College | Stabile zellinie, die in der lage ist, das replikationsgen des adenoassoziertenvirus zu exprimieren |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US5623054A (en) | 1994-06-23 | 1997-04-22 | The General Hospital Corporation | Crucifer AFT proteins and uses thereof |
| JPH10511264A (ja) | 1994-12-06 | 1998-11-04 | ターゲティッド ジェネティックス コーポレイション | 高力価組換えａａｖベクターの生成のためのパッケージング細胞株 |
| ES2150832B1 (es) | 1996-06-12 | 2001-06-16 | Fichtel & Sachs Ag | Dispositivo de maniobra para la maniobra, en particular maniobra neumatica, de un embrague de friccion. |
| AU5603998A (en) | 1996-12-18 | 1998-07-15 | Targeted Genetics Corporation | Recombinase-activatable AAV packaging cassettes for use in the production of AV vectors |
| GB9712370D0 (en) * | 1997-06-14 | 1997-08-13 | Aepact Ltd | Therapeutic systems |
| US6146874A (en) | 1998-05-27 | 2000-11-14 | University Of Florida | Method of preparing recombinant adeno-associated virus compositions |
| EP1074617A3 (en) * | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers for synthesising full-length cDNA and their use |
| CA2387785A1 (en) * | 1999-11-04 | 2001-05-10 | Incyte Genomics, Inc. | Human transferase molecules |
| AU2001234944A1 (en) * | 2000-02-03 | 2001-08-14 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| US20030175925A1 (en) * | 2001-02-27 | 2003-09-18 | Oleg Kurnasov | Nicotinamide ribonucleoside kinase |
| EP1588163A2 (en) * | 2003-01-23 | 2005-10-26 | Eirx Therapeutics Ltd | Kinases and gpcrs involved in apoptosis |
| ES2567135T3 (es) * | 2003-08-29 | 2016-04-20 | The Brigham And Women's Hospital, Inc. | Derivados de hidantoína como inhibidores de necrosis celular |
-
2005
- 2005-02-09 AU AU2005211773A patent/AU2005211773B2/en not_active Ceased
- 2005-02-09 EP EP05722944A patent/EP1723227A4/en not_active Withdrawn
- 2005-02-09 WO PCT/US2005/004337 patent/WO2005077091A2/en active Application Filing
- 2005-02-09 JP JP2006553250A patent/JP2007521835A/ja active Pending
- 2005-02-09 CA CA002555675A patent/CA2555675A1/en not_active Abandoned
-
2006
- 2006-04-20 US US11/912,400 patent/US8197807B2/en active Active
- 2006-10-04 US US11/542,832 patent/US20070027095A1/en not_active Abandoned
-
2012
- 2012-04-12 US US13/445,289 patent/US8383086B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007521835A5 (ja) | ||
| MX2009002920A (es) | Tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos. | |
| MX2009011359A (es) | Derivados de pirimidinona y sus metodos de uso. | |
| NL300889I2 (nl) | Trifluridine in combinatie met tipiracilhydrochloride | |
| WO2008082602A3 (en) | Compounds and pharmaceutical compositions for the treatment of liver disorders | |
| TW200740452A (en) | Therapeutic gastrodia extracts | |
| TR201820868T4 (tr) | Sindirilemeyen oligosakkritler içeren besin bileşimi. | |
| MX2010001560A (es) | Composicion farmaceutica que comprende un inhibidor de sglt2 en combinacion con un inhibidor de dpp-iv. | |
| MX2010004450A (es) | Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119. | |
| Zorzi et al. | A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium | |
| MY152037A (en) | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative | |
| MX2009011358A (es) | Derivados de pirimidinona y metodos para su uso. | |
| WO2007023154A3 (de) | EISEN(III)-KOMPLEXVERBINDtMGEN ZUR BEHANDLUNG VON EISENMANGEL-ZUSTÄNDEN BEI PATIENTEN MIT CHRONISCH-ENTZÜNDLICHER DARMERKRANKUNG | |
| NO20090590L (no) | Metabolisme modulatorer samt behandling av lidelser relatert dertil | |
| TW200637849A (en) | Kinase inhibitors | |
| WO2007084450A3 (en) | Cannibinoid receptor modulators | |
| NO20054382L (no) | Diarylsykloalkylderivater, deres fremstilling og deres anvendelse som legemiddel | |
| BRPI0922796A2 (pt) | Comprimido farmacêutico para administração por via oral e método de fabricação do mesmo | |
| Nase et al. | Reduced perivascular PO2 increases nitric oxide release from endothelial cells | |
| Sun et al. | Excess nicotinamide inhibits methylation-mediated degradation of catecholamines in normotensives and hypertensives | |
| WO2008149802A1 (ja) | アンドログラホリドを有効成分とする抗疲労剤及び経口組成物 | |
| FR2921927B1 (fr) | Imidazo°1,2-a!quinoxalines et derives pour le traitement des cancers | |
| JP2009537554A5 (ja) | ||
| Manjunath et al. | Adenosine and adenosine receptors: newer therapeutic perspective | |
| UA99598C2 (ru) | Применение экстракта эвкалипта для лечения или профилактики расстройств, являющихся следствием нарушения обратного захвата дофамина и/или серотонина, и/или норадреналина |